Evidence based medicine and justice: a framework for looking at the impact of EBM upon vulnerable or disadvantaged groups

This article examines the implicit promises of fairness in evidence based medicine (EBM), namely to avoid discrimination through objective processes, and to distribute effective treatments fairly. The relationship between EBM and vulnerable groups (such as those disadvantaged by virtue of poverty, ethnicity, age, gender, mental health problems or similar) is examined. Several aspects of EBM are explored: the way evidence is created (commissioning and design of, and participation in research), and the way evidence is applied in clinical care and health policy. This analysis suggests that EBM turns our attention away from social and cultural factors that influence health and focuses on a narrow biomedical and individualistic model of health. Those with the greatest burden of ill health are left disenfranchised, as there is little research that is relevant to them, there is poor access to treatments, and attention is diverted away from activities that might have a much greater impact on their health.

[1]  Jonathan A C Sterne,et al.  Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. , 2001, BMJ.

[2]  Richard Horton,et al.  Medical journals: evidence of bias against the diseases of poverty , 2003, The Lancet.

[3]  Shah Ebrahim,et al.  Dietary fat intake and prevention of cardiovascular disease: systematic review , 2001, BMJ : British Medical Journal.

[4]  Jeroan J Allison,et al.  Relation of race and sex to the use of reperfusion therapy in Medicare beneficiaries with acute myocardial infarction. , 2000, The New England journal of medicine.

[5]  H. Kohl Physical activity and cardiovascular disease: evidence for a dose response. , 2001, Medicine and science in sports and exercise.

[6]  W. McCaskill-Stevens,et al.  Participation of minorities in cancer research: the influence of structural, cultural, and linguistic factors. , 2000, Annals of epidemiology.

[7]  T. Dent,et al.  From guidance to practice: Why NICE is not enough , 2002, BMJ : British Medical Journal.

[8]  D Elbourne,et al.  Involving consumers in designing, conducting, and interpreting randomised controlled trials: questionnaire survey , 2001, BMJ : British Medical Journal.

[9]  D. Horrobin Are large clinical trials in rapidly lethal diseases usually unethical? , 2003, The Lancet.

[10]  M. Christian,et al.  How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Bailar,et al.  Selection and description of cancer clinical trials participants—Science or happenstance? , 2002, Cancer.

[12]  H. Matthews Racial, Ethnic and Gender Differences in Response to Medicines , 1995, Drug metabolism and drug interactions.

[13]  Malcolm A. Smith,et al.  Equal Participation of Minority Patients in U.S. National Pediatric Cancer Clinical Trials , 1997, Journal of pediatric hematology/oncology.

[14]  D. Banks,et al.  Participation of racial/ethnic groups in clinical trials and race-related labeling: a review of new molecular entities approved 1995-1999. , 2001, Journal of the National Medical Association.

[15]  W. Rogers Evidence‐based medicine in practice: limiting or facilitating patient choice? , 2002, Health expectations : an international journal of public participation in health care and health policy.

[16]  B Starfield,et al.  New paradigms for quality in primary care. , 2001, The British journal of general practice : the journal of the Royal College of General Practitioners.

[17]  P. Sidley Doctor reprimanded for giving antiretroviral drug to baby who was raped , 2002, British medical journal.

[18]  W. McCaskill-Stevens,et al.  Participation of Minorities in Cancer Research , 2000 .

[19]  Peter E. Hilsenrath,et al.  The World Health Report 2000 , 2002 .

[20]  P. Rochon,et al.  Reporting of gender-related information in clinical trials of drug therapy for myocardial infarction. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[21]  Harlan M Krumholz,et al.  Representation of the elderly, women, and minorities in heart failure clinical trials. , 2002, Archives of internal medicine.

[22]  L. Szczech,et al.  Healthcare system interventions for inequality in quality: corrective action through evidence-based medicine. , 2002, Journal of the National Medical Association.

[23]  F. McAlister,et al.  The Treatment and Prevention of Coronary Heart Disease in Canada: Do Older Patients Receive Efficacious Therapies? , 1999 .

[24]  J. M. Macfie “Single White Male” , 1961 .

[25]  J. Johnson,et al.  Influence of race or ethnicity on pharmacokinetics of drugs. , 1997, Journal of pharmaceutical sciences.

[26]  M. Kagawa-Singer Improving the validity and generalizability of studies with underserved U.S. populations expanding the research paradigm. , 2000, Annals of epidemiology.

[27]  Anne L. Taylor SERMs, Ethnicity, and Clinical Trials , 2001, Annals of the New York Academy of Sciences.

[28]  A. Avenell,et al.  Systematic review of randomised controlled trials , 2018 .

[29]  K. Burke NICE may fail to stop “postcode prescribing,” MPs told , 2002, BMJ : British Medical Journal.

[30]  European Cooperative Study Group,et al.  Translation of clinical trials into practice: a European population-based study of the use of thrombolysis for acute myocardial infarction , 1996, The Lancet.

[31]  M Sculpher,et al.  Effectiveness, efficiency, and NICE , 2001, BMJ : British Medical Journal.

[32]  G. A. Alexander,et al.  Racial/ethnic patterns of cancer in the United States, 1988-1992. , 1996 .

[33]  L A Moyé,et al.  Evaluation of ethnic minorities and gender effects in clinical trials: opportunities lost and rediscovered. , 2001, Journal of the National Medical Association.